Evidence map›Paper›PMID 32707835›Full record

ArticleCancers2020

Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer.

Elsa Arbajian, Mattias Aine, Anna Karlsson, Johan Vallon-Christersson, Hans Brunnström, Josef Davidsson, Sofie Mohlin, Maria Planck, Johan Staaf

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. CATA: a comprehensive chromatin accessibility database for cancer.Database : the journal of biological databases and curation · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Elsa ArbajianDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, SE 22381 Lund, Sweden.ORCID 0000-0002-1484-0073
Mattias AineDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, SE 22381 Lund, Sweden.
Anna KarlssonDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, SE 22381 Lund, Sweden.
Johan Vallon-ChristerssonDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, SE 22381 Lund, Sweden.
Hans BrunnströmDivision of Pathology, Department of Clinical Sciences Lund, Lund University, SE 22100 Lund, Sweden.ORCID 0000-0001-7402-138X
Josef DavidssonDivision of Molecular Hematology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, SE 22184 Lund, Sweden.
Sofie MohlinDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Medicon Village, SE 22381 Lund, Sweden.ORCID 0000-0002-2458-3963
Maria PlanckDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, SE 22381 Lund, Sweden.
Johan StaafDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, SE 22381 Lund, Sweden.ORCID 0000-0001-5254-5115
Lund University · SE

Funding

Barncancerfonden TJ2016-0057BioCARE a Strategic Research Program at Lund University Translational teamsCancerfonden CAN 2015/1097Fru Berta Kamprads Stiftelse BKS 27/16Governmental Funding ALF Project grantsGunnar Nilssons Cancerstiftelse GN-2018-5Sjöberg Foundation A translational approach to lung cancer therapyStiftelsen Jubileumsklinikens Forskningsfond mot Cancer 164161
6 · The paper itself

Abstract

Lung cancer is the worldwide leading cause of death from cancer. Epigenetic modifications such as methylation and changes in chromatin accessibility are major gene regulatory mechanisms involved in tumorigenesis and cellular lineage commitment. We aimed to characterize these processes in the context of neuroendocrine (NE) lung cancer. Illumina 450K DNA methylation data were collected for 1407 lung cancers including 27 NE tumors. NE differentially methylated regions (NE-DMRs) were identified and correlated with gene expression data for 151 lung cancers and 31 human tissue entities from the Genotype-Tissue Expression (GTEx) consortium. Assay for transposase-accessible chromatin sequencing (ATAC-seq) and RNA sequencing (RNA-seq) were performed on eight lung cancer cell lines, including three NE cell lines, to identify neuroendocrine specific gene regulatory elements. We identified DMRs with methylation patterns associated with differential gene expression and an NE tumor phenotype. DMR-associated genes could further be split into six functional modules, including one highly specific gene module for NE lung cancer showing high expression in both normal and malignant brain tissue. The regulatory potential of NE-DMRs was further validated in vitro using paired ATAC- and RNA-seq and revealed both proximal and distal regulatory elements of canonical NE-marker genes such as CHGA, NCAM1, INSM1, as well as a number of novel candidate markers of NE lung cancer. Using multilevel genomic analyses of both tumor bulk tissue and lung cancer cell lines, we identified a large catalogue of gene regulatory elements related to the NE phenotype of lung cancer.

Indexed as

ATAC-seqDNA methylationlung cancerneuroendocrine lung canceropen chromatin

Identifiers

PMID32707835
PMCPMC7464146
OpenAlexW3044819378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.